سعر كبرجامون Cabergamoun‏ 2 قرص 0.5 مجم 2026

Cabergoline 0.5 mg tablets (dopamine D2 agonist, prolactin inhibitor), pack of 2.

• Most common adverse reactions (incidence >10%): nausea, headache and dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Uncontrolled hypertension; known hypersensitivity to ergot derivatives; history of cardiac valvular disorders or pericardial fibrosis; history of pleural, pulmonary or retroperitoneal fibrotic disorders.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cardiac valvulopathy and pericardial fibrosis: perform echocardiography before treatment and every 6 to 12 months during treatment; discontinue if new valvular disease is diagnosed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Risk of pleural, retroperitoneal and pulmonary fibrosis, orthostatic hypotension, and impulse control disorders or compulsive behaviours.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Dopamine D2 antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide)Concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)

• If conception occurs during therapy, discontinue if risks to mother or fetus outweigh benefits; in general avoid dopamine agonists during pregnancy and the postpartum period.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not recommended in postpartum women who are breastfeeding or planning to breastfeed.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Cabergoline: Dopaminergic ergoline derivative that directly stimulates D2 dopamine receptors on pituitary lactotrophs, giving potent, long-lasting inhibition of prolactin secretion (UK Dostinex SmPC section 5.1).